Financial PerformanceThe company is expected to significantly reduce net debt in 2024 and to show a net cash position from 2025, enhancing its financial stability and potentially increasing its appeal to investors.
Product ApprovalThe new haemo-concentrators of the group have recently obtained FDA approval, which may lead to increased market share and revenue growth, especially in the lucrative US healthcare market.
ValuationThe stock is perceived as undervalued by the market, trading at attractive multiples with a high free cash flow yield, suggesting a potential upside for investment return.